JW Lifescience Past Earnings Performance
Past criteria checks 4/6
JW Lifescience's earnings have been declining at an average annual rate of -2.4%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 4.4% per year. JW Lifescience's return on equity is 17.7%, and it has net margins of 13.6%.
Key information
-2.4%
Earnings growth rate
-1.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 4.4% |
| Return on equity | 17.7% |
| Net Margin | 13.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Apr 20
Introducing JW Lifescience (KRX:234080), A Stock That Climbed 36% In The Last Year
Mar 11What Type Of Shareholders Make Up JW Lifescience Corporation's (KRX:234080) Share Registry?
Feb 21Is JW Lifescience Corporation (KRX:234080) A Smart Pick For Income Investors?
Feb 02
We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease
Jan 12Is It Smart To Buy JW Lifescience Corporation (KRX:234080) Before It Goes Ex-Dividend?
Dec 23Is JW Lifescience Corporation's (KRX:234080) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 23How Much Did JW Lifescience's(KRX:234080) Shareholders Earn From Share Price Movements Over The Last Three Years?
Nov 27Revenue & Expenses BreakdownBeta
How JW Lifescience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 206,860 | 28,144 | 15,100 | 5,161 |
| 30 Sep 23 | 203,466 | 22,454 | 14,598 | 4,768 |
| 30 Jun 23 | 200,051 | 20,722 | 14,271 | 4,768 |
| 31 Mar 23 | 195,087 | 17,989 | 14,212 | 4,956 |
| 31 Dec 22 | 188,931 | 14,961 | 13,358 | 5,737 |
| 30 Sep 22 | 183,113 | 12,133 | 13,358 | 6,289 |
| 30 Jun 22 | 175,624 | 13,250 | 11,139 | 7,752 |
| 31 Mar 22 | 171,226 | 12,000 | 11,095 | 7,803 |
| 31 Dec 21 | 169,817 | 12,914 | 12,908 | 6,242 |
| 30 Sep 21 | 170,039 | 5,623 | 13,052 | 5,385 |
| 30 Jun 21 | 174,823 | 9,668 | 13,124 | 5,224 |
| 31 Mar 21 | 179,657 | 15,906 | 12,907 | 4,971 |
| 31 Dec 20 | 183,521 | 17,300 | 13,180 | 5,195 |
| 30 Sep 20 | 183,449 | 27,971 | 13,309 | 5,218 |
| 30 Jun 20 | 181,525 | 25,088 | 13,598 | 5,058 |
| 31 Mar 20 | 175,937 | 23,015 | 13,766 | 4,762 |
| 31 Dec 19 | 170,221 | 21,938 | 13,833 | 3,583 |
| 30 Sep 19 | 164,794 | 21,366 | 13,745 | 2,922 |
| 30 Jun 19 | 161,964 | 21,485 | 12,938 | 2,091 |
| 31 Mar 19 | 156,833 | 18,703 | 13,331 | 1,424 |
| 31 Dec 18 | 155,230 | 15,821 | 13,636 | 1,249 |
| 30 Sep 18 | 154,069 | 14,363 | 13,935 | 968 |
| 30 Jun 18 | 151,388 | 13,671 | 13,902 | 730 |
| 31 Mar 18 | 148,331 | 14,997 | 12,893 | 488 |
| 31 Dec 17 | 143,600 | 16,783 | 12,223 | 399 |
| 30 Sep 17 | 139,234 | 16,681 | 11,361 | 524 |
| 30 Jun 17 | 133,223 | 15,922 | 11,449 | 606 |
| 31 Mar 17 | 133,299 | 15,314 | 11,507 | 602 |
| 31 Dec 16 | 132,290 | 15,162 | 11,312 | 665 |
| 30 Sep 16 | 129,096 | 15,416 | 11,852 | 536 |
| 30 Jun 16 | 129,223 | 14,496 | 11,288 | 498 |
| 31 Mar 16 | 127,272 | 14,097 | 10,754 | 454 |
| 31 Dec 15 | 125,950 | 12,864 | 10,535 | 399 |
| 31 Dec 14 | 111,121 | 9,357 | 9,137 | 342 |
| 31 Dec 13 | 88,614 | 1,633 | 7,968 | 396 |
Quality Earnings: A234080 has high quality earnings.
Growing Profit Margin: A234080's current net profit margins (13.6%) are higher than last year (7.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A234080's earnings have declined by 2.4% per year over the past 5 years.
Accelerating Growth: A234080's earnings growth over the past year (88.1%) exceeds its 5-year average (-2.4% per year).
Earnings vs Industry: A234080 earnings growth over the past year (88.1%) exceeded the Pharmaceuticals industry 36.1%.
Return on Equity
High ROE: A234080's Return on Equity (17.7%) is considered low.